このエントリーをはてなブックマークに追加
ID 54507
JaLCDOI
FullText URL
Thumnail 70_4_295.pdf 1.83 MB
Author
Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Koichiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Mitsui, Yosuke Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kubota, Risa Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshioka, Takashi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ariyoshi, Yuichi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kobayashi, Yasuyuki Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kitagawa, Masashi Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tanabe, Katsuyuki Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sugiyama, Hiroshi Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Jun Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Masami Center for Innovative Clinical Medicine, Okayama University Hospital
Watanabe, Toyohiko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hotta, Katsuyuki Center for Innovative Clinical Medicine, Okayama University Hospital
Nasu, Yasutomo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Abstract
Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
Keywords
end-stage renal disease
immunosuppression
kidney transplantation
Amo Type
Clinical Study Protocols
Published Date
2016-08
Publication Title
Acta Medica Okayama
Volume
volume70
Issue
issue4
Publisher
Okayama University Medical School
Start Page
295
End Page
297
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2016 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT